Colorectal Cancer: Prevention and Management of Metastatic Disease

被引:42
|
作者
Sugarbaker, Paul H. [1 ]
机构
[1] Washington Canc Inst, Washington, DC 20010 USA
关键词
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; SYSTEMIC CHEMOTHERAPY; SURGICAL-TREATMENT; RANDOMIZED-TRIAL; ADJUVANT THERAPY; MITOMYCIN-C; HIGH-RISK; LIVER;
D O I
10.1155/2014/782890
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This paper compared the similarities and differences of the two most common types of colorectal cancer metastases. The treatment of liver metastases by surgery combined with systemic chemotherapy was explained. The different natural history of liver metastases as compared to peritoneal metastases and the possibility for prevention of peritoneal metastases were emphasized. Perioperative cancer chemotherapy or second-look surgery must be considered as individualized treatments of selected patients who have small volume peritoneal metastases or who are known to be at risk for subsequent disease progression on peritoneal surfaces. However, the fact that peritoneal metastases, when diagnosed in the follow-up of colorectal cancer patients, can be cured with a combination of cytoreductive surgery and hyperthermic perioperative chemotherapy cannot be ignored. Careful follow-up and timely intervention in colorectal cancer patients with progressive disease are a necessary part of the management strategies recommended by the multidisciplinary team. After a critical evaluation of the data currently available, these strategies for prevention and management of colorectal metastases are presented as the author's recommendations for a high standard of care. As more information becomes available, modifications may be necessary.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Viewing Metastatic Colorectal Cancer as a Curable Chronic Disease
    Chua, Terence C.
    Liauw, Winston
    Chu, Francis
    Morris, David L.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (01): : 77 - 80
  • [42] METASTATIC COLORECTAL CANCER IN CROATIA - COST OF DISEASE STUDY
    Bencina, G.
    VALUE IN HEALTH, 2016, 19 (07) : A728 - A728
  • [43] Metastatic colorectal cancer outcome and fatty liver disease
    Antoine Brouquet
    Bernard Nordlinger
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 : 266 - 267
  • [44] Management of colorectal cancer: A role for genetics in prevention and treatment?
    Sengupta, Neel
    Gill, Kathryn A.
    MacFie, Tammie S.
    Lai, Cecilia S.
    Suraweera, Nirosha
    Mcdonald, Sarah
    Silver, Andrew
    PATHOLOGY RESEARCH AND PRACTICE, 2008, 204 (07) : 469 - 477
  • [45] PATTERNS OF CARE IN THE WORKUP AND MANAGEMENT OF NON-METASTATIC AND METASTATIC COLORECTAL CANCER
    Seal, B.
    Shermock, K. M.
    Asche, C., V
    Kreilick, C.
    Tangirala, M.
    Cameron, J.
    Kish, J.
    Zagadailov, E. A.
    Eaddy, M.
    VALUE IN HEALTH, 2015, 18 (03) : A191 - A191
  • [46] Molecular targeting in colorectal cancer and the role of KRAS mutation testing in the management of metastatic colorectal cancer
    McIntire, Maria G.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S22 - S22
  • [47] DISEASE PREVENTION - SCREENING SIGMOIDOSCOPY FOR COLORECTAL-CANCER
    SELBY, JV
    LANCET, 1993, 341 (8847): : 728 - 729
  • [48] Nutritional genomics and disease prevention: a case for colorectal cancer
    Abernathy, Breann E.
    Chung, Erica
    Muscoplat, Charles C.
    AGRO FOOD INDUSTRY HI-TECH, 2015, 26 (05): : 8 - 13
  • [49] Mesalazine and the prevention of colorectal cancer in inflammatory bowel disease
    Bos, C. L.
    Richel, D. J.
    Peppelenbosch, M. P.
    INTESTINAL INFLAMMATION AND COLORECTAL CANCER, 2007, 158 : 226 - 235
  • [50] Clinical management of metastatic colorectal cancer in the era of precision medicine
    Ciardiello, Fortunato
    Ciardiello, Davide
    Martini, Giulia
    Napolitano, Stefania
    Tabernero, Josep
    Cervantes, Andres
    CA-A CANCER JOURNAL FOR CLINICIANS, 2022, 72 (04) : 372 - 401